No profile data available.
BeOne Medicines AG (ONC) is a healthcare company in the blood cancer treatment drugs industry, based in Basel, Switzerland, with about 12,000 full-time employees.
It reported revenue of $5.34 billion for fiscal year 2025, up 40.2% from fiscal year 2024, and net income of $286.93 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.71 billion, up 29.6% from a year before. United States was its largest region in fiscal year 2025, with 54% of revenue. Its market capitalization was $40.33 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
BeOne Medicines reported $5.34 billion in revenue for fiscal year 2025, up 40.2% from $3.81 billion in fiscal year 2024. In Q2 2026 revenue was $1.71 billion.
United States: 54% of revenue by region in fiscal year 2025, followed by China (31%).
$40.33 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Genmab A/S (GMAB), Legend Biotech Corporation (LEGN), Sellas Life Sciences Group, Inc. (SLS), Ascentage Pharma Group International (AAPG).